Analysts expect that Alliqua Biomedical Inc (NASDAQ:ALQA) will report sales of $5.16 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Alliqua Biomedical’s earnings. The highest sales estimate is $5.50 million and the lowest is $4.83 million. Alliqua Biomedical reported sales of $4.94 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.5%. The firm is scheduled to announce its next earnings report on Tuesday, March 6th.

On average, analysts expect that Alliqua Biomedical will report full year sales of $5.16 million for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post sales of $23.38 million per share, with estimates ranging from $22.46 million to $24.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Alliqua Biomedical.

Several research firms recently commented on ALQA. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Alliqua Biomedical in a research note on Monday, September 18th. Zacks Investment Research raised shares of Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Tuesday, September 12th. Finally, ValuEngine upgraded shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $11.25.

An institutional investor recently raised its position in Alliqua Biomedical stock. Renaissance Technologies LLC boosted its stake in Alliqua Biomedical Inc (NASDAQ:ALQA) by 54.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 632,800 shares of the company’s stock after buying an additional 222,400 shares during the quarter. Renaissance Technologies LLC’s holdings in Alliqua Biomedical were worth $319,000 at the end of the most recent quarter.

Shares of Alliqua Biomedical (NASDAQ ALQA) opened at $2.13 on Tuesday. Alliqua Biomedical has a one year low of $1.99 and a one year high of $8.50.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/05/5-16-million-in-sales-expected-for-alliqua-biomedical-inc-alqa-this-quarter.html.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Get a free copy of the Zacks research report on Alliqua Biomedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alliqua Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical Inc and related companies with MarketBeat.com's FREE daily email newsletter.